Physician

Daniel L Venarske, M.D

According to 2025 Medicare claims, Daniel Venarske, M.D (NPI: 1003892357) practices allergy/immunology in the Jackson, MS market, with the plurality of this provider's patient population coming from Rankin, MS. This provider's primary affiliated billing organization is MISSISSIPPI ASTHMA & ALLERGY CLINIC PA (NPI: 1902882251; TIN: 640502151) and primary practice location at 39216-4829.

Venarske's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 317 traditional Medicare patients, billed 49,118 HCPCS/CPT codes, and received $1,018,422 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,534 prescription claims across 273 beneficiaries totaling $427,300 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 236 claims. Open Payments data shows 153 records totaling $39,190. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $70,714 to $1,018,422. Similarly, Part D prescription costs have moved sharply higher in recent years, from $124,490 to $427,300. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $1,046 to $5,225.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	245	7,318	$70,714
2016	292	8,144	$76,336
2017	295	8,445	$77,762
2018	308	8,532	$82,113
2019	332	13,280	$160,078
2020	341	19,710	$349,086
2021	319	28,405	$633,598
2022	308	34,961	$787,217
2023	325	46,020	$926,438
2024	317	49,118	$1,018,422

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	148	855	$124,490
2016	178	863	$84,107
2017	186	1,004	$102,740
2018	185	1,168	$121,586
2019	210	1,321	$168,872
2020	233	1,394	$186,111
2021	209	1,288	$206,901
2022	221	1,292	$292,660
2023	230	1,265	$686,549
2024	273	1,534	$427,300

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	47	$437
2017	N/R	34	$102
2018	N/R	108	$28,981
2019	N/R	129	$45,164
2020	N/R	68	$53,400
2021	N/R	127	$112,919
2022	N/R	132	$192,408
2023	N/R	261	$397,014
2024	N/R	236	$347,812

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	141	247	$78
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	145	185	$56
94010	Test to measure expiratory airflow and volume	115	175	$17
95165	Professional service for preparation and provision of 1 or more antigens	137	4,756	$9
95117	Professional service for multiple injections of allergen	78	1,657	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	73	2,730	$51,899
Spiriva Respimat	Tiotropium Bromide	15	990	$17,172
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	17	810	$16,989
Breo Ellipta	Fluticasone/Vilanterol	40	1,230	$14,747
Advair Hfa	Fluticasone Propion/Salmeterol	46	1,380	$14,609

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1558	Injection, immune globulin (xembify), 100 mg	N	N/R	26	$138,248
J1557	Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	19	$69,047
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$67,947
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	13	$53,037
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	45	$14,477

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	153	$39,190	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel L. Venarske, M.D?

Tedicare shows public-source Medicare data for Daniel L. Venarske, M.D (NPI 1003892357), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel L. Venarske, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel L. Venarske, M.D?

Daniel L. Venarske, M.D is linked to MISSISSIPPI ASTHMA & ALLERGY CLINIC PA (billing NPI 1902882251) in the available physician profile data.

Does Daniel L. Venarske, M.D have Open Payments data?

Daniel L. Venarske, M.D has 153 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.